DrugPatentWatch

Competitive intelligence on small-molecule drugs and the 80,000 patents covering them

Simple flat-rate subscription plans

Ultimate Plan

$495/ month or  $2,495/ year

Tradename: GLEEVEC

Summary for Tradename: GLEEVEC

Patents:5
Applicants:1
NDAs:2
Suppliers: see list2
2013 Sales:$1,896,982,000
drug
patent expirations by year for
 GLEEVEC

Pharmacology for Tradename: GLEEVEC

Drug ClassKinase Inhibitor
Mechanism of ActionProtein Kinase Inhibitors

Clinical Trials for: GLEEVEC

Pilot Study of Gleevec/Imatinib Mesylate (STI-571, NSC 716051) in Neurofibromatosis (NF1) Patient With Plexiform Neurofibromas
Status: Active, not recruiting Condition: Neurofibromatosis; Neurofibromas

Therapy of Early Chronic Phase CML With Gleevec
Status: Completed Condition: Leukemia, Myeloid, Chronic-Phase

Dose Escalation Study of Gleevec and Chlorambucil in Previously Treated Chronic Lymphocytic Leukemia Patients
Status: Terminated Condition: Chronic Lymphocytic Leukemia

Efficacy of 400 Mg Versus 800 Mg Imatinib in Chronic Myeloid Leukemia in Chronic Phase Patients - TOPS (Tyrosine Kinase Inhibitor Optimization and Selectivity)
Status: Terminated Condition: Leukemia, Myeloid, Chronic Phase

Crossover Study to Compare Pharmacokinetic Property of SYO-1126 and Glivec Film Coated Tab in Healthy Male Volunteers
Status: Completed Condition: Healthy

Ph I Gleevec in Combo w RAD001 + Hydroxyurea for Pts w Recurrent MG
Status: Completed Condition: Glioblastoma; Gliosarcoma

Imatinib Mesylate, Busulfan, Fludarabine, and Antithymocyte Globulin for CML Patients
Status: Terminated Condition: Leukemia

Glivec/Gleevec Pediatric (Age 1 to Less Than 4) PK Study in CML, Ph+ ALL Patients and Other Glivec/GleevecĀ® Indicated Hematological Disorders.
Status: Terminated Condition: Chronic Myeloid Leukemia (CML); Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL); Other Glivec/Gleevec Indicated Hematological Disorders (HES, CEL, MDS/ MPN)

Gleevec/Taxol for Patients With Uterine Papillary Serous Carcinoma
Status: Active, not recruiting Condition: Uterine Cancer

Effect of Antacids on GleevecĀ® in Healthy Volunteers
Status: Completed Condition: Healthy

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Novartis
GLEEVEC
imatinib mesylate
CAPSULE;ORAL021335May 10, 2001DISCNNo5,521,184*PED<disabled>Y<disabled>
Novartis
GLEEVEC
imatinib mesylate
CAPSULE;ORAL021335May 10, 2001DISCNNo6,894,051*PED<disabled>Y<disabled>
Novartis
GLEEVEC
imatinib mesylate
CAPSULE;ORAL021335May 10, 2001DISCNNo6,958,335*PED<disabled>Y<disabled>
Novartis
GLEEVEC
imatinib mesylate
CAPSULE;ORAL021335May 10, 2001DISCNNoRE43932*PED<disabled><disabled>
This preview shows a limited data set
Complete access is available with a Subscription
first patents previous patents next patents last patents

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: GLEEVEC

Drugname Dosage Strength RLD Submissiondate
imatinib mesylateTablets100 mg and 400 mgGleevec3/12/2007
imatinib mesylateCapsules400 mgGleevec1/24/2014

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000  2001  2002  2003  2004  2005  2006  2007  2008  2009 
 2010  2011  2012  2013 

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: BiotechUBiotechBlogJournal of Commercial Biotechnology

`abc